A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Business/Administrative decision to pursue other programs/assets within the oncology portfolio. Not due to any detected safety signals or requests from regulatory authorities.

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

DRUG: maplirpacept (PF-07901801)
DRUG: Glofitamab
DRUG: Obinutuzumab

Sponsor

Pfizer

Collaborators

[object Object]